Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Keywords: Indacaterol Glycopyrronium Bromide COPD bronchodilation
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 449
Healthy volunteers: no

Brief summary:
This study assessed the efficacy, safety and tolerability of the co-administration of NVA237 plus indacaterol taken once daily versus indacaterol taken once daily in patients with moderate to severe Chronic Obstructive Pulmonary Disease.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: NVA237 50 µg and indacaterol 150 µg intervention 2: Placebo to NVA237 and indacaterol 150 µg
Intervention descriptions: intervention 1: NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation. intervention 2: Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.

Protocol document: